Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) announced that CEO Adam Levy will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022. The presentation is scheduled for September 14, from 9:00 A.M. to 9:30 A.M. Eastern Time. Interested investors can contact their H.C. Wainwright representative or email NEXGEL@kcsa.com for 1x1 meetings. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications, having over two decades of experience in developing these innovative solutions.
NEXGEL reported a 35% year-over-year revenue growth to $561 thousand for Q2 2022, showing a 42% sequential increase. The rise is attributed to successful launches and demand for branded products, such as MEDAGEL Pro Pads. Gross profit improved to $101 thousand, with an 18% margin. However, operating expenses rose to $819 thousand, driven by increased R&D investments and higher SG&A costs. As of June 30, 2022, cash and equivalents stood at $9.7 million, ensuring a solid financial position for ongoing growth initiatives.
NEXGEL (NASDAQ: NXGL) will report its financial and operating results for Q2 2022 on August 10, 2022, after market close. Following the release, a conference call will be held at 4:30 P.M. ET the same day. Interested individuals can join the call via a U.S. toll-free number or international dial-in options, and a webcast will be available on the company’s Investor Relations website. A replay of the call will be accessible until August 17, 2022. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications.
NEXGEL (NASDAQ: NXGL, NXGLW) has launched the MEDAGEL Hydroliner Pro pads designed to protect eyelashes during cosmetic services like extensions and lifts. These pads offer a breathable, flexible, and skin-friendly alternative to traditional options, preventing slippage while being gentle on sensitive skin. They aim to enhance client comfort, allowing for easy removal and replacement during the application process. This product marks NEXGEL's first proprietary business-to-business offering, expanding its innovative hydrogel product line.
NEXGEL (NASDAQ: NXGL, NXGLW) has launched a partnership with Partners for World Health to provide humanitarian support in Ukraine. For every two boxes of SilverSeal® purchased, one will be donated to those in need. In June, 458 boxes were donated, equating to 1,832 healing patches. CEO Adam Levy emphasized the importance of treating skin injuries in crisis zones. The initiative addresses urgent medical needs amid ongoing conflict, aiming to deliver essential supplies through various shipping methods.
NEXGEL, Inc. (NASDAQ: NXGL) reported a 48% year-over-year revenue increase to $396 thousand for Q1 2022, driven by new product launches in its consumer segment. The company introduced two new OTC products: the MEDAGEL ClearComfort Hydrogel Patch and the MEDAGEL Bug Bite Relief Patch. Gross loss improved to $22 thousand from $42 thousand last year, although operating expenses rose to $790 thousand. Cash reserves decreased to $10.5 million due to principal payments on notes payable. The company forecasts continued revenue growth.
NEXGEL, a provider of high-water-content hydrogel products, will announce its first quarter 2022 financial and operating results on May 12, 2022, after market closure. A conference call is scheduled for 4:30 PM/ET on the same day to discuss these results. The call can be accessed via toll-free numbers and will be webcast live, with an archive available for 90 days. The company specializes in skin-friendly hydrogels, developing over 200 combinations using natural ingredients for long-term wear with minimal irritation.
NEXGEL, a provider of high-water-content hydrogel products, announces CEO Adam Levy's participation at the Planet MicroCap Showcase 2022 from May 3-5, 2022, in Las Vegas. Levy's presentation is scheduled for May 4, 2022, at 10:30 AM PT, with a webcast accessible for those unable to attend. Interested investors can book 1x1 meetings during the conference. NEXGEL specializes in gentle skin patches utilizing over 200 formulations and has been developing hydrogels for over 20 years.
NexGel, Inc. (NASDAQ: NXGL), a leader in ultra-gentle hydrogel products, will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. CEO Adam Levy's presentation will be available on-demand at the conference's start. Attendees can register to join here. With over two decades of experience, NexGel specializes in high-water-content hydrogels for healthcare and consumer use.
NEXGEL, a provider of hydrogel products, reported a significant 130% year-over-year revenue growth for 2021, totaling $1.55 million. The fourth quarter saw a revenue increase of 428%, amounting to $533 thousand.
The company completed a $14.2 million IPO and has a cash reserve of $13.35 million as of December 31, 2021, supporting future growth initiatives. Operating expenses rose to $2.58 million, primarily due to one-time costs from the IPO. Despite growth, NEXGEL reported an EBITDA loss of $2.27 million for the year.